• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Enveric Biosciences Inc (NQ: ENVB )

    0.4831 -0.0161 (-3.23%)
    Streaming Delayed Price Updated: 1:14 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Enveric Biosciences Inc

    < Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Enveric Biosciences Advances Testing Of Its Non-Hallucinogenic Psychedelic
    Enveric Biosciences announces positive preclinical results for EB-003, showcasing its potential as a safe and effective treatment for mental health disorders. 
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Psychedelics 2.0: Companies Explore Safer, More Targeted Therapies
    Companies are developing safer, targeted psychedelic therapies aimed at reducing risks and improving mental health treatment options. 
    Via Benzinga
    Non-Hallucinogenic Psychedelic Treatment For Anxiety And Depression In Pre-Clinical Models: Enveric Biosciences' Breakthrough Research
    Psychedelics biotech company Enveric Biosciences (NASDAQ: ENVB) has presented research highlighting the company's lead compound, EB-003 at the 7th Neuropsychiatric Drug Summit. The conference is being... 
    Via Benzinga
    Why Is Enveric Biosciences (ENVB) Stock Up 18% Today?
    Enveric Biosciences stock is up on Tuesday with heavy trading of ENVB shares despite a lack of news from the company this morning. 
    Via InvestorPlace
    ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q2 2024
    ENVB stock results show that Enveric Biosciences beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    Why Is Imunon (IMNN) Stock Up 259% Today?
    Imunon stock is up on Tuesday with heavy trading of IMNN shares after posting positive results from a Phase 2 clinical trial. 
    Via InvestorPlace
    Why Is Ekso Bionics (EKSO) Stock Down 15% Today?
    Ekso Bionics stock is down on Tuesday as investors in the company react to its lackluster earnings report for the second quarter of the year. 
    Via InvestorPlace
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    Pre-market stock movers are a hot topic as we jump into all of the biggest news that has shares heading higher and lower on Tuesday morning! 
    Via InvestorPlace
    Why F5 Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Non-Hallucinogenic Psychedelic Treatment For Mental Health Disorders Shows Potential To Be Dosed Orally
    Via Benzinga
    New Patented Psychedelic Drug Brings Hope For Brain Disorder Therapies
    Enveric Biosciences has been granted a U.S. patent for EB-002, enhancing protection for treatments targeting brain neurological disorders, including depression and anxiety. 
    Via Benzinga
    Topics Intellectual Property
    Exposures Intellectual Property
    ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q1 2024
    ENVB stock results show that Enveric Biosciences beat analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    'Psychedelics-Inspired' Meds For Depression, Anxiety, Addiction Producer Trims Q1 Net Loss YoY, Increases Cash On Hand
    Enveric Biosciences reported on Wednesday financial results for the first quarter of 2024 ended March 31, 2024."We believe the first quarter of 2024 was a highly productive period for Enveric as the... 
    Via Benzinga
    Microdosing For Depression: Psychedelics Biotech Signs $66.5M Non-Binding Deal To Out-License Novel Psilocin Prodrug Candidate
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Cannabinoids With Chemotherapy For Breast Cancer: Psychedelics Biotech Inks $61M License Deal For Patented Methods
    The news of the licensee deal comes on the heels of the DEA's move to reschedule marijuana, one source of cannabinoids, as a Schedule III controlled substance. 
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the J.P. Morgan Retail Roundup investor conference where the company reportedly... 
    Via Benzinga
    Exposures Glyphosate
    ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q4 2023
    ENVB stock results show that Enveric Biosciences beat analyst estimates for earnings per share the fourth quarter of 2023. 
    Via InvestorPlace
    Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
    Via Benzinga
    Enveric Biosciences Optimistic On Q4 And Full-Year Results: 'Psychedelic-Inspired' Meds For Future Growth
    Via Benzinga
    Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    Nasdaq Down 100 Points; US Housing Starts Surge In February
    U.S. stocks traded mixed this morning, with the Nasdaq Composite falling around 100 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.11% to 38,831.86 while the NASDAQ fell... 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter EPS results. 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.